Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Raphael Reports Positive Cannabinoid Therapy Results for Arthritis
Details : Company’s cannabinoid-based formula is being investigated for the management of rheumatoid arthritis (RA).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable